Roche’s IMpower 132 hits on progression-free survival, but Merck remains in control — for now — on frontline lung cancer
Roche just leaped forward in the rankings of the big league lung cancer game. But they’re still not ready yet to challenge a dominant Merck …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
